Ligand Receives $47 Million from WuXi Biologics for Expansion of Worldwide OmniAb® Platform License Agreement
Ligand Prices Offering of $650 Million of Convertible Senior Notes
Ligand Announces Proposed Offering of $650 Million of Convertible Senior Notes
Ligand to Participate in Upcoming Investor Conferences
Ligand Reports First Quarter 2018 Financial Results
Ligand to Report First Quarter 2018 Results on May 8th
Ligand Enters into Agreement with venBio to Make Worldwide OmniAb® Platform License Accessible to Portfolio Companies
Ligand Licenses Glucagon Receptor Antagonist Program to Roivant Sciences
Ligand to Participate in Two Upcoming Investor Conferences
Ligand Reports Fourth Quarter and Full Year 2017 Financial Results
Ligand to Report Fourth Quarter and Full Year 2017 Results on February 21st
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Ferring Pharmaceuticals
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Contrast Agents for Diagnostic Imaging
Ligand Enters into Worldwide OmniAb® Platform License Agreement with Glenmark Pharmaceuticals
